SynthesisHuman vaccines & immunotherapeutics2026
Meningococcal meningitis in India: An expert consensus on use of MCVs.
Synthesis in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive meningococcal disease (IMD) is a significant but under-recognized public health challenge in India, marked by rapid progression, high mortality, and severe sequelae. This consensus document, developed from literature review, outbreak analyses, and deliberations by 14 Indian experts, highlights outbreaks from 1966 (Delhi: 616 cases, case fatality ration: CFR 20.9%) to 2022-2023 (Kolkata). Serogroup A remains predominant, with emerging serogroups C, W, and Y. Systematic review evidence shows 12.1% prevalence in epidemics (CFR 12.8%) and 0.76% in endemic settings (CFR 3.0%), though true burden is underestimated due to weak surveillance. IMD shows bimodal age distribution, highest in children < 5 y (61.8%) and adolescents. MenACWY conjugate vaccines show 95.7-99.5% seroprotection across serogroups. Experts recommend vaccination at 9-12 months with booster at 10-11 y, mandatory reporting, sentinel surveillance, and clinician awareness. The roadmap stresses awareness, short-term surveillance, and long-term data generation toward National Immunization Program inclusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.